Sucampo Pharmaceuticals — Investor Presentation (October 2013)
7 slides from Sucampo Pharmaceuticals's investor presentation, Oct 16, 2013
Slide 1: AMITIZA Clinical Development & Life Cycle Management
AMITIZA Clinical Development & Life Cycle Management Pediatric Constipation + Very common GI complaint in children’? + WW prevalence ~18% 21? Initiate P3 Pediat Functional Conaipaten ogram by end of 2013 Boiss o3 ‘Abdominal reciogrsph Takeda: funding 70% of ch err development costs throughout the co
Slide 2: Sucampo Prostone Pipeline
Sucampo Prostone Pipeline lon Channel “eile for Lumbar — al Ste Lumbar Spinal St sis Degenerative change in lumbar spine Cobiprostone for Oral Mucositis Oral Mucositis treatment-limiting of age by lumbar spinal stenosis!® globally cancer patients in the U.S."*; oral mucositis affects Si Sone Ongoing
Slide 3: Clinical Focus: Stage of Clinical Development
CLINICAL FOCUS STAGE OF CLINICAL DEVELOPMENT LEAD COMPOUNDS DISCOVERY | PRECLINICAL PHASE 2 PHASE 3 a. i AMITIZA Pediatric Constipation FPFV 2H13 PO Ion Channel Activator Spinal Stenosis eee 1 IV lon Channel Activator Spinal Stenosis Phase 1b Cobiprostone Oral Mucositis 4013 SUCCESSFULLY COMPLETED I
Slide 4: Key Facts
Key Facts. trading Symbol ( porporale Headquarters 13), 52-Week Range $6.50, $10.48 to $4.41 SCMP (NASDAQ) Total Revenue Shares outa (10- 8) daily Volume te (90rI8 ave Cash & Equivalents 42.5M (1 class of common stock) Net Income AMITIZA U.S. Net Sales (as reported by Takeda): SUCAMPO The Science of
Slide 5: Upcoming milestones
2H 2013 Q4 Third quarter cic p Pediatric F ip Start of phase ip Oral Mucositi Top-I i for Lumbar Spinal Stenosis 4Q 2013/4 CEO Transition (EST) | 4H)2014 ] Qi | AMITIZA ind / U.K. | $ SUCAMPO The Science of Innovation
Slide 6: Key Facts
Key Facts Tading Symbol SCMP (NASDAQ) lebt ash & Equivalents Total Operating Expense Total Revenue c jerporate fisodouatiere Bethesda, MD ), 52- | $6.50, $10.48 to leek Range $4.41 42.5M (1 class of 3) common stock) ily y 121,810 average) $276.1M Market Capitalization (10- 11-13) Enterprise Value (1
Slide 7: U.S. Patent No. and expiration
Uss.PatentNo. | Expires: 5,204,958 2014 14,01 2020 588t74 2020 6,962,288 2022 7,064,148 2022 747,067 2020 7795312 2004 9,026,505 2027 3071 613 2000 9.008; 2021 9097, 648 2000 0,097,658 2002 114,88 2020 9,598,688 2027 2002 and therapeutic use (treating constipation) ‘Genes Ot ites valent sonpans inve
Sucampo Pharmaceuticals — Investor Presentation (October 2013) on 6ix